Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shoichi Ohwada

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Pharmacology Research & Perspectives|August 29, 2018
Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studiesKaren Brown, Jeanne Mendell, Shoichi Ohwada, et al.
Cancer Chemotherapy and Pharmacology|February 2, 2017
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancerToshio Shimizu, Kimio Yonesaka, Hidetoshi Hayashi, et al.
International Journal of Hematology|September 2, 2019
Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 studyTakeshi Takahashi, Kensuke Usuki, Kosei Matsue, et al.
International Journal of Hematology|July 31, 2019
Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 studyKensuke Usuki, Hiroshi Handa, Ilseung Choi, et al.
Cancer Science|July 26, 2016
Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancerHirofumi Mukai, Toshiaki Saeki, Kenjiro Aogi, et al.
Clinical Pharmacology in Drug Development|January 29, 2024
Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and ChinaJunyuan Qi, Ilseung Choi, Shuichi Ota, et al.
Cancer Medicine|January 9, 2023
Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancerKoichi Goto, Yoshimasa Shiraishi, Haruyasu Murakami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II TrialIan E Krop, Norikazu Masuda, Toru Mukohara, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Pharmacology Research & Perspectives|August 29, 2018
Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studiesKaren Brown, Jeanne Mendell, Shoichi Ohwada, et al.
Cancer Chemotherapy and Pharmacology|February 2, 2017
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancerToshio Shimizu, Kimio Yonesaka, Hidetoshi Hayashi, et al.
International Journal of Hematology|September 2, 2019
Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 studyTakeshi Takahashi, Kensuke Usuki, Kosei Matsue, et al.
International Journal of Hematology|July 31, 2019
Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 studyKensuke Usuki, Hiroshi Handa, Ilseung Choi, et al.
Cancer Science|July 26, 2016
Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancerHirofumi Mukai, Toshiaki Saeki, Kenjiro Aogi, et al.
Clinical Pharmacology in Drug Development|January 29, 2024
Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and ChinaJunyuan Qi, Ilseung Choi, Shuichi Ota, et al.
Cancer Medicine|January 9, 2023
Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancerKoichi Goto, Yoshimasa Shiraishi, Haruyasu Murakami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II TrialIan E Krop, Norikazu Masuda, Toru Mukohara, et al.
Pageof 2